key: cord-0974001-0glsp26e
authors: Pizuorno, Antonio; Brim, Hassan; Ashktorab, Hassan
title: Gastrointestinal manifestations and SARS-CoV-2 infection
date: 2021-09-25
journal: Curr Opin Pharmacol
DOI: 10.1016/j.coph.2021.09.005
sha: 6bb3514a6ee2edd8bc509a3851aa0f9b8f261b15
doc_id: 974001
cord_uid: 0glsp26e

Since COVID-19 occurrence in late 2019, intense research efforts on an unprecedented scale have focused on the study of SARS CoV-2 entry mechanisms and clinical presentations. As for other coronaviruses, SARS-CoV-2 presents with extra-respiratory clinical manifestations like diarrhea, nausea, vomiting and abdominal pain which highlight that the gastrointestinal (GI) system as another viral target along with the typical presentations of COVID-19 which is characterized primarily by respiratory symptoms. The digestive system is involved in many systemic functions through the gut-brain-axis and systemic immunity modulation. Therefore, the GI system plays an important role in the presentation of the disease, pathogenesis, and possibly treatment outcome. This mini-review summarizes recent work to study SARS-CoV-2 infection as it relates to comorbidities, GI symptoms. This will help to strategize the priorities in understanding the impact of the virus on outcome in various aspects.

Coronaviruses are part of an Orthocoronavirinae subfamily within the Coronaviridae (Helmy, et al. 2020) . They are positive sense single stranded RNA viruses (Helmy, et al. 2020) . In December 2019, several patients with atypical pneumonia with no known origin were diagnosed in Wuhan, Hubei Province, China. After genomic analysis, it was established that this pneumonia was caused by a new Coronavirus named Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) (Li, et al. 2020a ). The associated disease was named COVID-19. As of May 10, 2021, more than 157 million positive confirmed cases and more than 3.2 million deaths attributed to the infection have been reported worldwide according to the Center for Systems Science and Engineering at John Hopkins University (Johns Hopkins University 2020). The World Health Organization declared that COVID-19 was a public health emergency and on March 11 of 2020 declared it a pandemic (WHO 2020) . At that time, there were no vaccines against SARS-CoV-2 or any specific treatment to fight the infection. Although some information was available from previous Coronaviruses' outbreaks and Middle East Respiratory Syndrome (MERS), the extent of SARS CoV-2 dissemination, its high rate of transmission, the variety of associated symptoms and the numbers of deaths caught clinicians, scientists and the general population off guard.

There were two prior similar short-lived pandemics namely the 2002 SARS CoV-1 and the 2012 MERS. SARS CoV-1 originated from and spread quickly in China with hundreds of deaths with a lethality rate of 11% (total reported cases: 8,422 and 916 deaths (Chan-Yeung and Xu 2003) . MERS emerged in 2012 in the Middle East, in Saudi Arabia, its mortality rate was high with around 37% (Al Sulayyim, et al. 2020) . Both viruses' origins were traced back to bats and both associated with overlapping similar symptoms such as fever, cough, dyspnea, and atypical pneumonia. Although both of these viruses affected the gastrointestinal (GI) tract with symptoms like diarrhea, patients with MERS had a higher prevalence of GI symptoms (Aleebrahim-Dehkordi, et al. 2021), a higher mortality rate, and more than 50% of the patients needed extreme treatment measures such as mechanical ventilation (in contrast to only 20% with SARS CoV-1) (Al-Dorzi, et al. 2016) . Since these two previous pandemics were short lived and geographically confined, not much attention was given to extra-pulmonary symptoms such as the ones reported in the GI system that can be responsible for some levels of infection dissemination through fecal-oral transmission.

J o u r n a l P r e -p r o o f Coronavirus entry is mediated by the viral spike (S) glycoprotein ( Figure 1 ) (Bosch, et al. 2003) . The Spike in the Coronaviruses is composed of a transmembrane trimetric glycoprotein protruding from the viral surface, which determines the diversity of coronaviruses and host tropism. The Spike comprises two functional subunits: S1 responsible for binding to the host cell receptor and S2 for the fusion of the viral and cellular membranes. Angiotensin converting enzyme 2 (ACE2) was identified as a functional receptor for SARS-CoV.

Most of the symptoms of the coronaviruses are primarily respiratory. The virus invades and infects the respiratory tract via the ACE2 receptor (Li, et al. 2020b) . It is very important to remark that ACE2 receptors are highly expressed along the GI tract. The viral protein spike binds to the cellular surface of ACE2, and is cleaved by the transmembrane serine protease 2 (TMPRSS2) to allow entry and subsequent propagation of the virus (Hoffmann, et al. 2020) . Both ACE2 and TMPRSS2 are expressed in the lung alveoli, esophageal cells but also on the absorptive enterocytes of the ileum and colon. The enterocytes of the small bowel are the cells that contain the highest amount of ACE2 receptors in the human body . The host response to infection to SARC-CoV-2 varies from mild to severe. Inflammatory response (involving dendritic cells and macrophages) are the first immune response for gaining adaptive immunity in alveola (Yoshikawa, et al. 2009 ). A recent study showed that the absence of a pro-inflammatory response in the GI system translates into downregulation of key inflammatory genes (e.g. IFNG, CXCL8, CXCL2, and IL1B) and reduction of pro-inflammatory dendritic cells compared with control individuals. Mortality rates in COVID-19 patients with GI symptoms was also reported to be lower than in patients without such symptoms, which prompted Livanos et al (Livanos, et al. 2020) to hypothesize that the GI system might be acting as a buffer in COVID-19 patients and GI symptoms are J o u r n a l P r e -p r o o f likely a way to attenuate COVID-19 impact in the host (Livanos, et al. 2021) . Another recent international study by Vanella et al. (Vanella, et al. 2021 ) revealed major GI mucosal damage in COVID-19 patients undergoing endoscopy, although this did not lead to prolonged hospitalization. In their cohort of 106 patients from the first wave of COVID-19 (February-May 2020), they found that almost half showed acute mucosal damage (found early on admission) and more than one-third had features of ischemic colitis; still the author recognizes their findings are from a highly selected cohort of less than 1% of admitted patients with COVID-19 and did not confirm an association between SARS CoV-2 infection and gastrointestinal ischemia. As such, it is very important to further dissect the short-and long-term effects of COVID-19 on the GI system from the occurrence of GI symptoms, to effects on GI organs and systemic effects, especially when the gut barrier integrity is breached. In fact, these observations become more significant in light of a recent study in non-human primate that showed that intra-gastric SARS CoV-2 injection led to the same systemic symptoms, including respiratory system, as a pulmonary SARS CoV-2 infection, pointing to the GI system as another potential point of entry of the virus to the host systems (Jiao, et al. 2021 ).

Multiple studies have reported the presence of the viral RNA in fecal samples or rectal swabs in patients with COVID-19. According to a study in China, 55 out of 93 patients had a positive PCR for SARS-CoV-2 RNA in the stool (59%) with a median duration of this positive PCR detection of 22 days (Zheng, et al. 2020a) . Generally, the viral loads from stool samples of COVID-19 patients tend to peak 2-3 weeks after the symptoms' onset and most of the time stay positive longer periods even after respiratory symptoms subside and respiratory specimens are negative for the viral RNA (Walsh, et al. 2020) , still one have to consider the presence of opportunistic bacterial pathogens and infectivity of the virus in both aerosol particles and stools (Zuo, et al. 2020 ). An in-vitro study showed that human duodenum enteroids excreted the virus from the apical side to the lumen of the gut suggesting the possibility of excreting the virus via the feces in patients with active disease (Cong and Ren 2014) . Another aspect to consider in respect of fecal-oral transmission of the virus is the lag time of the virus SARS-CoV-2 remains viable in the feces, although several studies has been made for aerosol transmission, there is only simulations in labs where the virus particles could live from 4 hours to up to 72 hours depending on surfaces, but still more investigation needs to be done in order to describe the transmissibility of the virus in the feces (van Doremalen, et al. 2020). There have been several studies that have addressed GI manifestations' prevalence in COVID-19 patients. A metaanalysis (Sultan, et al. 2020) , reported that in 10,676 COVID-19 patients, diarrhea had a prevalence of 7.7%, abdominal pain 3.6%, nausea and vomiting 7.8%, and in 3 out of 4 studies, viral shedding in stools was reported. It is important to note that this meta-analysis included patients mostly from China and USA. In comparison, a large dataset from Chile, reported (Diaz, et al. 2020 ) that diarrhea was present in 7.3%, and abdominal pain in 3.7% in a cohort of 7,016 patients. In the US which is the country with most positive confirmed cases in the world, Ashktorab et al (Ashktorab, et al. 2021a) reported that in 447 patients with a majority of them being African Americans, diarrhea was predominant in 19.45%, abdominal pain present in 15.8%. African Americans had the highest diarrhea prevalence of 22.4%. At least 24% of the total cohort had one or more GI symptoms.

As for Latin America, currently the epicenter of the pandemic, Ashktorab et. al (Ashktorab, et al. 2021b) reported that diarrhea, nausea, vomiting and abdominal pain, were highly prevalent, but not associated with higher mortality. In another study on an Iranian cohort, Mokarram et. al (Mokarram P 2021) reported nausea in 42.8%, diarrhea in 31.8%, vomiting in 26.8% and abdominal pain in 12%. This cohort of patients had an elevated liver enzyme profile as well (albumin, ALP, AST, ALT) in 26.3% of patients. Studies from China (Zheng, et al. 2020b ) reported low prevalence of diarrhea with only 8.1%, anorexia in 4.7% and nausea and vomiting in 4.3%. These differences in GI symptoms prevalence highlight the presence of regional differences that need to be further characterized for an efficient management of the patients at local levels; perhaps these differences may be justified by the presence of different spike protein mutations in the different strains of SARS-CoV-2 that are emerging currently, unfortunately there is not many literature in the respect of this issue.

It is important to remark that gastrointestinal manifestation were not only present in the adult population but so does for the children infected by COVID-19. Chiappini et al. (Chiappini, et al. 2020 ) study compared different patient pools from different regions of the world in a meta-analysis for over 1200 patients, vomiting was present in 9.3% and diarrhea was present in 8.8% of the pediatric population.

Beyond the presence of ACE2 and TMPRSS2 markers in the GI system, it is very likely that part of the GI symptoms that a sizable portion of COVID-19 patients experience, occur through a disturbance of the gut microbiome in these patients. Indeed, several studies reported a major dysbiosis (persisted imbalance of gut microbiome) in these patients as a result of COVID-19 (Segal, et al. 2020 ). This dysbiosis persisted weeks after discharge from hospital and respiratory clearance of the virus. Such dysbiosis is likely to continue exerting some low-grade inflammation that is thought to be associated with persistence, recurrence and in some cases new symptoms in these patients. Recently Yeoh et. Al (Yeoh, et al. 2021 ) study shows how gut microbiota composition of patients with COVID-19 during hospitalization is correlated with plasma concentrations of several cytokines, chemokines, and inflammation markers, suggesting that the gut microbiota could play a role in modulating host immune response and potentially influence disease severity and outcomes. This opens to a potential role played by gut microbiome in COVID-19 that could allow the use of a gut-microbiome-based risk profile to identify individuals at risk of severe disease or downstream inflammatory symptoms.

The COVID-19 scenario is very complex in terms of characterization of the disease for prevention, diagnostics and treatment. As of now, different variants have been discovered since the beginning of the pandemic all around the world and each one discovered in different regions making the panorama different in each area which leads up to a tropism in the presentation of patients. Overall, the presentation of patients from the gastroenterological standpoint is the typical picture for diarrhea, nausea and vomiting for both adults and children; but one has to consider the presence of pre-existing conditions in those patients (specially gastrointestinal diseases), and how the gut microbiome axis influence the immune system in the setting of SARS-CoV-2 infection since it can be correlated to both treatments and outcomes.

If we take the 1899 Russian Influenza pandemic as an example, we are likely to be dealing with COVID-19associated symptoms for years to come. How would the current vaccination campaign affect the course of the pandemic is still unknown? Would there be different trajectories of the pandemic depending on the type of vaccines is also an open question? Do we need to supplement some probiotics with current vaccines or to patients who do not have access to vaccines, is also an area that will need to be further explored to mitigate COVID-19 systemic effects in general and the GI ones in particular.

The authors declare no conflicts of interest.

Acknowledgments: Julio Y Anaya-Covarrubias, from Universidad de Guadalajara.

J o u r n a l P r e -p r o o f covery from respiratory infection of SARS-CoV-2. Gut microbiota of patients with active SARS-CoV-2 GI infection was characterised by enrichment of opportunistic pathogens, loss of salutary bacteria and increased functional capacity for nucleotide and amino acid biosynthesis and carbohydrate metabolism.

Yeoh, Y. K., Zuo, T., Lui, G. C., Zhang, F., Liu, Q., Li, A. Y., Chung, A. C., Cheung, C. P., Tso, E. Y., Fung, K. S., Chan, V., Ling, L., Joynt, G., Hui, D. S., Chow, K. M., Ng, S., Li, T. C., Ng, R. W., Yip, T. C., Wong, G. L., … Ng, S. C. (2021). Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with 70(4) , 698-706. https://doi.org/10.1136/gutjnl-2020-323020. The gut microbiota dysbiosis after disease resolution could contribute to persistent symptoms, highlighting a need to understand how gut microorganisms are involved in inflammation and COVID-19. 

Authors acknowledge the importance of knowing previous Coronaviruses epidemics in the past but also emphasize different characteristics that make SARS-CoV-2 unique and the

This study from the first datasets of patients in China where the pandemic started, describes the epidemiology of the virus, how the virus disseminates person to person specially via respiratory droplets

** This study emphasizes the ways the SARS-Cov-2 attach to the ACE receptors in the lung but also on the gut which opens a new way for fecal-oral transmission, digestive disease and and extended description on the pathophysiology of COVID-19 with potential sites for treatment and vaccines

WHO Director General opening remarks at the media briefing on COVID-19

Demographic, clinical, and outcomes of confirmed cases of Middle East Respiratory Syndrome coronavirus (MERS-CoV) in Najran, Kingdom of Saudi Arabia (KSA); A retrospective record based study

Overall children as like in SARS-CoV and MERS-CoV epidemic were less affected than adults

Critically ill patients with Middle East respiratory syndrome coronavirus infection

Interestingly this study reports that of critically MERS-CoV patients, that 32% of the patients had gastrointestinal symptoms

The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex

The MERS-CoV Receptor DPP4 as a Candidate Binding Target of the SARS-CoV-2 Spike. iScience

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Specific ACE2 expression in small intestinal enterocytes may cause gastrointestinal symptoms and injury after 2019-nCoV infection

Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells

* Macrophages and Dendritic cells play a huge role in the pathogenesis and response to the SARS-CoV-2 infection. They prime naive T cells and phagocytosis. Other key molecules are IL-6 and IL-8

Gastrointestinal involvement attenuates COVID-19 severity and mortality. medRxiv : the preprint server for health sciences

Data found highlight that the absence of a general pro inflammatory state is frequently seen in patients with gastrointestinal symptoms

Gastrointestinal mucosal damage in patients with COVID-19 undergoing endoscopy: an international multicentre study

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China

SARS-CoV-2 detection, viral load and infectivity over the course of an infection

Although the duration of stool SARS-CoV-2 is longer than respiratory samples, it is now well known the significancy and the infectivity of it

Coronaviruses uses different ways to exit the infected cells (apical side, basolateral side or both)

AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19

Symptom Profiles and Risk Factors for Hospitalization in Patients With SARS-CoV-2 and COVID-19: A Large Cohort From South America

Elevated Liver Enzymes, Ferritin, C-reactive Protein, D-dimer, and Age Are Predictive Markers of Outcomes Among African American and Hispanic Patients With Coronavirus Disease

COVID-19 in Latin America: Symptoms, Morbidities, and Gastrointestinal Manifestations

Clinical characteristics, gastrointestinal manifestations and outcomes of COVID-19 patients in Iran; does the location matters?

Clinical characteristics and outcomes of COVID-19 patients with gastrointestinal symptoms admitted to Jianghan Fangcang Shelter Hospital in Wuhan

** The number of total T cells CD4 and CD8 T cells are reduced in patients with COVID-19

This study consisted of 10 experimental conditions involving SARS-CoV-2 and SARS-CoV-1 in five environmental conditions (aerosols, plastic, stainless steel, copper, and cardboard. SARS-CoV-2 can remain viable and infectious in aerosols for hours and

Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19